Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC)

Overview of attention for article published in Frontiers in oncology, March 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (70th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter: 10 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 8 Dimensions

Readers on

mendeley: 25 Mendeley

Summary X Facebook Dimensions citations

So far, Altmetric has seen 18 X posts from 10 X users, with an upper bound of 87,965 followers.

RT @weldeiry: Sharing & reminding colleagues I would’ve abandoned if no efficacy ⁦@FrontOncology⁩ Disease Control With FOLFIRI Plus Ziv-afl…

14 Feb 2022

Reply Repost Favourite

RT @weldeiry: Sharing & reminding colleagues I would’ve abandoned if no efficacy ⁦@FrontOncology⁩ Disease Control With FOLFIRI Plus Ziv-afl…

13 Feb 2022

Reply Repost Favourite

Sharing & reminding colleagues I would’ve abandoned if no efficacy ⁦@FrontOncology⁩ Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC) ⁦@BrownUCancer⁩ https:/

13 Feb 2022

Reply Repost Favourite

RT @weldeiry: But in Rhode Island, despite over 2-years of trying, we can’t @BrownUCancer @RIHospital collaborate with @flatironhealth due…

15 Jul 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 14 additional X posts.